BL
VIRX

Bleichroeder LP’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Bleichroeder LP’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-8,414
Closed -$99K – 62
2019
Q4 		$99K Buy
+8,414
New +$141K 0.02% 44

Other funds holding VIRX

ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Bleichroeder LP's VIRX Position: Q1 2020 in Review

Bleichroeder LP sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2020, closing a stake of 8,414 shares — an estimated $99K sold.

Bleichroeder LP first reported a position in VIRX in Q4 2019 and held it in 1 quarter. The position peaked at $99K in Q4 2019. 47 funds tracked by Wall St. Rank hold VIRX as of Q1 2020.

  • Bleichroeder LP reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Bleichroeder LP sold 8,414 Viracta Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $99K.
  • Bleichroeder LP first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2019 and held it in 1 quarter.
  • Bleichroeder LP's Viracta Therapeutics, Inc. Common Stock position peaked at $99K in Q4 2019.
  • 47 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Bleichroeder LP's 13F filing for Q1 2020, filed 14 May 2020.